HUTCHMED Receives ELUNATE® (fruquintinib) Marketing App

— First medicine approved under new “1+” mechanism by HKSAR Government, providing an important treatment option to patients in Hong Kong — — ELUNATE® is the first oral targeted therapy...

Related Keywords

Hong Kong , Cairo , Al Qahirah , Egypt , United States , Macau , Shanghai , China , Belgium , Belgian , American , Karen Atkin , Stephen Chan , Ahcene Djaballah , Caron Li , Gastroenterol Hepatol , Ben Atwell Alex Shaw , Zhou Yi , Nasdaq , Eli Lilly Company , China National Reimbursement Drug List , Exchange Commission , China National Medical Products Administration , Drug Administration , Journal Of The American Medical Association , China Limited Nasdaq , Hospital Authority , Stock Exchange Of Hong Kong , Linkedin , Poisons Board , Hong Kong Special Administrative Region , Executive Vice President , Chief Operating Officer , Vice President , Regional Markets , Medical Oncology , Eli Lilly , Fruquintinib Approval , American Medical Association , Securities Litigation Reform Act , Stock Exchange , Alex Shaw , Freddy Crossley , Daphne Zhang , Kong Cancer Registry , Colorectal Cancer , Rev Gastroenterol Hepatol , Clinical Cancer Res , Winding Road From Negative Predictive Factor , Positive Actionable , Markets ,